Cargando…
A Case of Idiopathic Thrombocytopenic Purpura After Booster Dose of BNT162b2 (Pfizer-Biontech) COVID-19 Vaccine
Vaccination is now considered the best measure in minimizing the morbidity and mortality from the Covid-19 pandemic. Almost all the vaccines are considered safe except for minor and occasional side effects. Some of the commonly reported complications from the COVID-19 vaccines are vaccine-induced th...
Autores principales: | Malayala, Srikrishna V, Papudesi, Bhavani N, Sharma, Rishika, Vusqa, Urwat T, Raza, Ambreen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607313/ https://www.ncbi.nlm.nih.gov/pubmed/34820240 http://dx.doi.org/10.7759/cureus.18985 |
Ejemplares similares
-
Immune Thrombocytopenic Purpura Following Pfizer-BioNTech COVID-19 Vaccine in an Elderly Female
por: Jasaraj, Ranjit B, et al.
Publicado: (2021) -
Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273) COVID-19 mRNA vaccines and hypersensitivity reactions
por: Haq, Hannah N., et al.
Publicado: (2022) -
Thrombocytopenic purpura with AstraZeneca but not Pfizer-BioNTech COVID-19 vaccine
Publicado: (2021) -
Covid-19-vaccine-pfizer-biontech: Thrombotic thrombocytopenic purpura: case report
Publicado: (2021) -
Covid-19-vaccine-pfizer-biontech/levofloxacin: Immune thrombocytopenic purpura: case report
Publicado: (2021)